科伦博泰生物-B：Inaugural year of commercialization-20260325

CMB International Global Markets | Equity Research | Company Update Kelun-Biotech (6990 HK) Kelun-Biotech (6990 HK) - 25 Mar 2026 Inaugural year of commercialization T Kelun-Biotech marks 2025 as its transformational commercialization inflection year, transitioning from a clinical-stage biotech to a biopharmaceutical company with four approved products and a robust revenue trajectory. The Company reported total revenue of RMB2.06bn (+6.5% YoY), with pharmaceutical product sales contributing RMB543mn—a testa ...